PRCT

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a surgical robotics company founded in 2007 and headquartered in Redwood City, California. The company went public in September 2021 and has established itself as a pioneer in robotic-assisted urological surgery. PROCEPT develops and commercializes the AquaBeam and HYDROS robotic systems, which utilize proprietary <b>Aquablation therapy</b> - a minimally invasive surgical technique that uses high-velocity saline to precisely remove prostate tissue for treating benign prostatic hyperplasia (BPH). The company has grown rapidly since its IPO, expanding its installed base from 130 systems worldwide in 2021 to over 500 systems by 2024, with strong presence in the United States and growing international operations.